Lupin launches Rocuronium Bromide Injection in United States

08 Nov 2023 Evaluate

Lupin has launched Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials, after Lupin’s alliance partner Caplin Steriles (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (USFDA). 

Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials is the generic version of Zemuron Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc and is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection (RLD: Zemuron) had estimated annual sales of $54 million in the U.S. (IQVIA MAT August 2023). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2290.15 -24.70 (-1.07%)
16-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.55
Dr. Reddys Lab 1275.05
Cipla 1298.80
Zydus Lifesciences 886.30
Lupin 2290.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×